App-Quantinova.ai

Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA

Thomas C R McDonnell - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Calcineurin inhibitors as adjunctive therapy for lupus nephritis: a retrospective study from two European centres

Alina Casian - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

Cyclosporine eent

Evaluating the prevalence of heavy menstrual bleeding (menorrhagia) in patients with systemic lupus erythematosus

Chris Wincup - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Marked improvement in symptoms of cerebral ischaemia in response to immunosuppressive therapy in severe supra-aortic Takayasu arteritis

Andrew Porter - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

N/A

Reducingthe need for temporal artery biopsy through a rheumatology-led fast trackultrasound service for giant cell arteritis

Vanessa Quick - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Prednisolone

Audit of temporal artery biopsy

Dimitrios Christidis - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Glucocorticoid

Measurement of oxygenation in nailfold capillaries: a feasibility study in patients with systemic sclerosis and healthy controls

Michael Berks - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Dermoscopy versus videocapillaroscopy in the assessment of nailfold capillaroscopy images in patients with systemic sclerosis and healthy controls

Graham Dinsdale - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

Isolated tuberculosis of the wrist: elusive but destructive

Zoe Rutter-Locher - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Tuberculosis

N/A

A multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice

Karl Gaffney - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

golimumab

Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials

Philip J Mease - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Apremilast

Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial

Iain McInnes - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Abatacept

Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study

Laura C Coates - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2

Hasan Tahir - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data

Hasan Tahir - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data

Arvind Kaul - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Methotrexate

Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

An audit assessing the appropriateness of MRI requests in patients with suspected inflammatory back pain

Katerina M Achilleos - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Efficacy and safety of ixekizumab at week 52 in biologic naïve patients with active psoriatic arthritis (SPIRIT-P1)

Eric Lespessailles - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Adalimumab

Quality of life estimation in economic evaluations and healthcare decision making: different approaches, different results. Results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS)

Gareth T Jones - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Filters

45280 Abstracts